Recurrent activating mutations in AHR act as drivers of urinary tract cancer
Bladder cancer has a high recurrence rate and low survival of advanced stage patients. Few genetic drivers of bladder cancer have thus far been identified. We performed in-depth structural variant analysis on whole-genome sequencing data of 206 metastasized urinary tract cancers. In ~10% of the patients, we identified recurrent in-frame deletions of exons 8 and 9 in the aryl hydrocarbon receptor gene (AHR{Delta}e8-9), which codes for a ligand-activated transcription factor. Pan-cancer analyses show that AHR{Delta}e8-9 is highly specific to urinary tract cancer and mutually exclusive with other bladder cancer drivers. In AHR{Delta}e8-9 the ligand-binding domain is disrupted and we show that this results in ligand-independent AHR-pathway activation. In bladder organoids, AHR{Delta}e8-9 induces a transformed phenotype that is characterized by upregulation of AHR target genes, downregulation of differentiation markers and upregulation of genes associated with stemness and urothelial cancer. Furthermore, AHR{Delta}e8-9 expression results in anchorage independent growth of bladder organoids, indicating tumorigenic potential. DNA-binding deficient AHR{Delta}e8-9 fails to induce transformation, suggesting a role for AHR target genes in the acquisition of the oncogenic phenotype. In conclusion, we show that AHR{Delta}e8-9 is a novel driver of urinary tract cancer and that the AHR pathway could be an interesting therapeutic target.